1
|
Uccelli L, Martini P, Urso L, Ghirardi T, Marvelli L, Cittanti C, Carnevale A, Giganti M, Bartolomei M, Boschi A. Rhenium Radioisotopes for Medicine, a Focus on Production and Applications. Molecules 2022; 27:5283. [PMID: 36014521 PMCID: PMC9412410 DOI: 10.3390/molecules27165283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 08/08/2022] [Accepted: 08/17/2022] [Indexed: 11/28/2022] Open
Abstract
In recent decades, the use of alpha; pure beta; or beta/gamma emitters in oncology, endocrinology, and interventional cardiology rheumatology, has proved to be an important alternative to the most common therapeutic regimens. Among radionuclides used for therapy in nuclear medicine, two rhenium radioisotopes are of particular relevance: rhenium-186 and rhenium-188. The first is routinely produced in nuclear reactors by direct neutron activation of rhenium-186 via 185Re(n,γ)186Re nuclear reaction. Rhenium-188 is produced by the decay of the parent tungsten-188. Separation of rhenium-188 is mainly performed using a chromatographic 188W/188Re generator in which tungsten-188 is adsorbed on the alumina column, similar to the 99Mo/99mTc generator system, and the radionuclide eluted in saline solution. The application of rhenium-186 and rhenium-188 depends on their specific activity. Rhenium-186 is produced in low specific activity and is mainly used for labeling particles or diphosphonates for bone pain palliation. Whereas, rhenium-188 of high specific activity can be used for labeling peptides or bioactive molecules. One of the advantages of rhenium is its chemical similarity with technetium. So, diagnostic technetium analogs labeled with radiorhenium can be developed for therapeutic applications. Clinical trials promoting the use of 186/188Re-radiopharmaceuticals is, in particular, are discussed.
Collapse
Affiliation(s)
- Licia Uccelli
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy
- Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy
| | - Petra Martini
- Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy
| | - Luca Urso
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy
- Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy
| | - Teresa Ghirardi
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy
| | - Lorenza Marvelli
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy
| | - Corrado Cittanti
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy
- Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy
| | - Aldo Carnevale
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy
- Radiology Unit, University Hospital, 44124 Ferrara, Italy
| | - Melchiore Giganti
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy
- Radiology Unit, University Hospital, 44124 Ferrara, Italy
| | - Mirco Bartolomei
- Nuclear Medicine Unit, University Hospital, 44124 Ferrara, Italy
| | - Alessandra Boschi
- Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, 44121 Ferrara, Italy
| |
Collapse
|
2
|
Nuclear data for light charged particle induced production of emerging medical radionuclides. RADIOCHIM ACTA 2022. [DOI: 10.1515/ract-2022-0011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Whatever the radionuclide to be used in nuclear medicine, it is essential to know the expected yield during the production process, but also of all the possible radionuclidic impurities coproduced, that can have an impact on the product final quality, as well as in the related waste management. The availability of the majority of emerging radioisotopes, including the theranostic ones or pairs, is mainly limited by the fact that, for most of them, the optimal production route still needs to be strengthened if not defined in some cases. The aim of this work is to present a review on the charged particle induced nuclear cross sections to produce some emerging radionuclides for medical applications to show that all types of projectiles should be considered in the quest of producing medical radionuclides. An accurate analysis of the production routes is presented for some radionuclides (67Cu, 47Sc, 89Zr, 103Pd, 186gRe, 97Ru, 211At) chosen as examples to highlight (i) how the quality of the final product strongly depends on the chosen target/projectile/energy parameters set, (ii) how deuteron production routes may sometimes be more effective than the proton ones or lead to a different impurity profile and (iii) how α-particle beams may allow to bypass the limitations occurring when using Z = 1 beams. An overview of possible advantages and drawbacks of the cited production routes and of potential cross sections that still need to be measured, is also reported.
Collapse
|
3
|
Moiseeva AN, Aliev RA, Kormazeva ES, Latushkin ST, Malamut TY, Makoveeva KA, Novikov VI, Unezhev VN, Furkina EB, Zagryadskiy VA. Cross sections of 3He-particle induced reactions on 186W. Appl Radiat Isot 2021; 170:109609. [PMID: 33571734 DOI: 10.1016/j.apradiso.2021.109609] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Revised: 01/11/2021] [Accepted: 01/19/2021] [Indexed: 10/22/2022]
Abstract
Irradiation of 186W targets by 3He particles was carried out. For the first time the cross sections for the reactions of production of 183, 184, 186, 188Re, 183, 185Os, 187W were measured by the stack foil technique in the 3He energy range of 15-45 MeV. The results were compared to the data from the TENDL-2019 library. Using the experimental excitation functions, the thick target yields of medically relevant rhenium radioisotopes were calculated.
Collapse
Affiliation(s)
- A N Moiseeva
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia.
| | - R A Aliev
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - E S Kormazeva
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - S T Latushkin
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - T Yu Malamut
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - K A Makoveeva
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - V I Novikov
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - V N Unezhev
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - E B Furkina
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| | - V A Zagryadskiy
- National Research Center "Kurchatov Institute", 1, Akademika Kurchatova pl., 123182, Moscow, Russia
| |
Collapse
|
4
|
Khandaker MU, Nagatsu K, Minegishi K, Zhang MR, Jalilian AR, Bradley DA. Cyclotron production of no carrier added 186gRe radionuclide for theranostic applications. Appl Radiat Isot 2020; 166:109428. [PMID: 32979754 DOI: 10.1016/j.apradiso.2020.109428] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 09/07/2020] [Accepted: 09/14/2020] [Indexed: 11/24/2022]
Abstract
186gRe (T1/2 = 3.7183 d, E(β-)mean = 346.7 keV, I(β-)mean = 92.59%), a mixed beta and γ-emitter shows great potential for use in theranostic applications. The dominant 185Re(n,γ) route, via use of a nuclear reactor, provides 186gRe in carrier added form with low specific activity, while cyclotrons offer no carrier-added (NCA) high specific activity production of 186gRe. However, to be able to select the best possible nuclear reaction and to optimize the production route via the use of a cyclotron, information on the excitation function for the reaction of interest as well as for the competing reactions is necessary. Accordingly, we have conducted a detailed study of the excitation functions for natW(d, x) reactions in seeking optimized parameters for the NCA production of 186gRe. Noting a discrepancy among the experimental data, we made an evaluation of the available literature, finally selecting optimum parameters for the production of 186gRe via the 186W(d,2n)186Re reaction. These beam parameters were then used for batch production of 186gRe by irradiating an enriched 186W metallic powder target, followed by a subsequent automated chemical separation process. The preliminary results show 98.1% radionuclidic purity of 186gRe at 8 h subsequent to the End of Bombardment (EOB), offering the potential for use in clinical applications.
Collapse
Affiliation(s)
- Mayeen Uddin Khandaker
- Centre for Biomedical Physics, School of Healthcare and Medical Sciences, Sunway University, 47500 Bandar Sunway, Selangor, Malaysia, & Department of Physics, University of Malaya, 50603, Kuala Lumpur, Malaysia.
| | - Kotaro Nagatsu
- National Institutes for Quantum and Radiological Sciences and Technology, 4-9-1 Anagawa, Inage, Chiba, 263-8555, Japan.
| | - Katsuyuki Minegishi
- National Institutes for Quantum and Radiological Sciences and Technology, 4-9-1 Anagawa, Inage, Chiba, 263-8555, Japan
| | - Ming-Rong Zhang
- National Institutes for Quantum and Radiological Sciences and Technology, 4-9-1 Anagawa, Inage, Chiba, 263-8555, Japan
| | - Amir R Jalilian
- Department of Nuclear Science and Applications, International Atomic Energy Agency (IAEA), A- 1400 Vienna, Austria
| | - D A Bradley
- Centre for Biomedical Physics, School of Healthcare and Medical Sciences, Sunway University, 47500 Bandar Sunway, Selangor, Malaysia, & Department of Physics, University of Malaya, 50603, Kuala Lumpur, Malaysia; Department of Physics, University of Surrey, Guildford, Surrey GU2 7XH, UK
| |
Collapse
|
5
|
Baumeister JE, Mitchell AW, Kelley SP, Barnes CL, Jurisson SS. Steric influence of salicylaldehyde-based Schiff base ligands on the formation of trans-[Re(PR 3) 2(Schiff base)] + complexes. Dalton Trans 2019; 48:12943-12955. [PMID: 31393493 DOI: 10.1039/c9dt02630d] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Complexes of the type trans-[Re(PR3)2(Schiff base)]+ (R = ethyl and/or phenyl) 2-7 were prepared by the reaction of (nBu4N)[ReOCl4] with H2sal2en or H2sal2ibn followed by addition of a tertiary phosphine. The trans-[Re(PR3)2(sal2en)]+ complexes 2-4 were stable in solution, whereas the trans-[Re(PR3)2(sal2ibn)]+ complexes 6-7 were observed to convert to their corresponding cis-[ReO(PR3)(sal2ibn)]+ products through a process involving ligand dissociation, metal oxidation, and Schiff base ligand rearrangement. The conversion of the trans-[Re(PR3)2(sal2ibn)]+ complexes is likely driven by steric interactions between the bulky backbone gem-dimethyl groups of the sal2ibn ligand and the phosphine ligands. These complexes were isolated and characterized by 1H and 13C NMR, FT-IR spectroscopy, cyclic voltammetry, and single crystal X-ray diffraction. The results reported herein provide insight into the factors that drive trans-[Re(PR3)2(Schiff base)]+ complex formation. This will aid in the development of novel 186/188Re therapeutic agents and the design of novel bifunctional N2O2 Schiff base ligands.
Collapse
Affiliation(s)
- Jakob E Baumeister
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA.
| | - Andrew W Mitchell
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA.
| | - Steven P Kelley
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA.
| | - Charles L Barnes
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA.
| | - Silvia S Jurisson
- Department of Chemistry, University of Missouri, Columbia, MO 65211, USA.
| |
Collapse
|
6
|
Baumeister JE, Reinig KM, Barnes CL, Kelley SP, Jurisson SS. Technetium and Rhenium Schiff Base Compounds for Nuclear Medicine: Syntheses of Rhenium Analogues to 99mTc-Furifosmin. Inorg Chem 2018; 57:12920-12933. [PMID: 30239194 DOI: 10.1021/acs.inorgchem.8b02156] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Rhenium, the third-row congener of technetium, is often used to develop the macroscopic chemistry of potential 99mTc diagnostic radiopharmaceuticals. The rhenium analogues to 99mTc-furifosmin are being developed for potential radiotherapy of multidrug-resistant tumors. Complexes of the form trans-[MIII(PR3)2(N2O2-Schiff base)]+ are of interest for the potential imaging and treatment of multidrug-resistant tumors. Reaction of the tetradentate Schiff ligand 4,4'-[(1 E,1' E)-[ethane-1,2-diylbis(azanylylidene)]bis(methanylylidene)]bis(2,2,5,5-tetramethyl-2,5-dihydrofuran-3-ol) (tmf2enH2) with the M(V) starting materials ( nBu4N)[TcOCl4] and ( nBu4N)[ReOCl4] gave the monomeric products trans-[TcOCl(tmf2en)] and trans-[ReOCl(tmf2en)], respectively. Reduction of in situ formed trans-[ReOCl(tmf2en)] by various tertiary phosphines yielded disubstitued Re(III) products of the general type trans-[ReIII(PR3)2(tmf2en)]+. The rhenium(III) compounds were found to be water-soluble and stable in aqueous solution. Reversible ReIII/ReIV and ReIII/ReII redox processes were observed at about 0.8-0.9 and -0.65 to -0.8 V, respectively, for each of the rhenium(III) species. Reaction of in situ formed trans-TcOCl(tmf2en) with triethylphosphine yielded the reduced, disubstituted trans-[Tc(PEt3)2(tmf2en)]PF6. A reversible TcIII/TcII redox couple was observed for the technetium(III) species, about 200 mV less negative than their rhenium(III) analogues, in addition to an irreversible TcIII/TcIV process. All compounds were characterized using conventional spectroscopic techniques, single-crystal X-ray crystallography, and cyclic voltammetry.
Collapse
Affiliation(s)
- Jakob E Baumeister
- Department of Chemistry , University of Missouri , Columbia , Missouri 65211 , United States
| | - Kimberly M Reinig
- Department of Chemistry , University of Missouri , Columbia , Missouri 65211 , United States
| | - Charles L Barnes
- Department of Chemistry , University of Missouri , Columbia , Missouri 65211 , United States
| | - Steven P Kelley
- Department of Chemistry , University of Missouri , Columbia , Missouri 65211 , United States
| | - Silvia S Jurisson
- Department of Chemistry , University of Missouri , Columbia , Missouri 65211 , United States
| |
Collapse
|
7
|
Balkin ER, Gagnon K, Dorman E, Emery R, Li Y, Wooten AL, Smith BE, Strong KT, Pauzauskie PJ, Fassbender ME, Cutler CS, Ketring AR, Jurisson SS, Wilbur DS. Scale-up of high specific activity 186gRe production using graphite-encased thick 186W targets and demonstration of an efficient target recycling process. RADIOCHIM ACTA 2017. [DOI: 10.1515/ract-2017-2780] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Production of high specific activity 186gRe is of interest for development of theranostic radiopharmaceuticals. Previous studies have shown that high specific activity 186gRe can be obtained by cyclotron irradiation of enriched 186W via the 186W(d,2n)186gRe reaction, but most irradiations were conducted at low beam currents and for short durations. In this investigation, enriched 186W metal targets were irradiated at high incident deuteron beam currents to demonstrate production rates and contaminants produced when using thick targets. Full-stopping thick targets, as determined using SRIM, were prepared by uniaxial pressing of powdered natural abundance W metal or 96.86% enriched 186W metal encased between two layers of graphite flakes for target material stabilization. An assessment of structural integrity was made on each target preparation. To assess the performance of graphite-encased thick 186W metal targets, along with the impact of encasing on the separation chemistry, targets were first irradiated using a 22 MeV deuteron beam for 10 min at 10, 20, and 27 μA, with an estimated nominal deuteron energy of 18.7 MeV on the 186W target material (after energy degradation correction from top graphite layer). Gamma-ray spectrometry was performed post EOB on all targets to assess production yields and radionuclidic byproducts. The investigation also evaluated a method to recover and recycle enriched target material from a column isolation procedure. Material composition analyses of target materials, pass-through/wash solutions and recycling process isolates were conducted with SEM, FTIR, XRD, EDS and ICP-MS spectrometry. To demonstrate scaled-up production, a graphite-encased 186W target made from recycled 186W was irradiated for ~2 h with 18.7 MeV deuterons at a beam current of 27 μA to provide 0.90 GBq (24.3 mCi) of 186gRe, decay-corrected to the end of bombardment. ICP-MS analysis of the isolated 186gRe solution provided data that indicated the specific activity of 186gRe in this scaled-up production run was 2.6±0.5 GBq/μg (70±10 Ci/mg).
Collapse
Affiliation(s)
- Ethan R. Balkin
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Katherine Gagnon
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Eric Dorman
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Robert Emery
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Yawen Li
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - A. Lake Wooten
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| | - Bennett E. Smith
- Chemistry Department , University of Washington , Seattle, WA 98195 , USA
| | - Kevin T. Strong
- Materials Science and Engineering Department , University of Washington , Seattle, WA 98195 , USA
| | - Peter J. Pauzauskie
- Materials Science and Engineering Department , University of Washington , Seattle, WA 98195 , USA
| | | | - Cathy S. Cutler
- Medical Isotope Research and Production Program , Brookhaven National Laboratory , Upton, NY 11973 , USA
- University of Missouri Research Reactor Center , Columbia, MO 65211 , USA
| | - Alan R. Ketring
- University of Missouri Research Reactor Center , Columbia, MO 65211 , USA
| | - Silvia S. Jurisson
- Department of Chemistry , University of Missouri , Columbia , MO 65211, USA
| | - D. Scott Wilbur
- Department of Radiation Oncology , University of Washington , Seattle, WA 98195 , USA
| |
Collapse
|
8
|
Mastren T, Radchenko V, Bach HT, Balkin ER, Birnbaum ER, Brugh M, Engle JW, Gott MD, Guthrie J, Hennkens HM, John KD, Ketring AR, Kuchuk M, Maassen JR, Naranjo CM, Nortier FM, Phelps TE, Jurisson SS, Wilbur DS, Fassbender ME. Bulk production and evaluation of high specific activity 186gRe for cancer therapy using enriched 186WO3 targets in a proton beam. Nucl Med Biol 2017; 49:24-29. [DOI: 10.1016/j.nucmedbio.2017.02.006] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2016] [Revised: 02/13/2017] [Accepted: 02/28/2017] [Indexed: 12/31/2022]
|
9
|
Feng Y, Phelps TE, Carroll V, Gallazzi F, Sieckman G, Hoffman TJ, Barnes CL, Ketring AR, Hennkens HM, Jurisson SS. Chemistry and radiochemistry of As, Re and Rh isotopes relevant to radiopharmaceutical applications: high specific activity radionuclides for imaging and treatment. Dalton Trans 2017; 46:14677-14690. [DOI: 10.1039/c7dt02407j] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Advances in production, separation, target recovery, and chelation chemistry of high specific activity radionuclides will promote new theranostic agent development.
Collapse
Affiliation(s)
- Yutian Feng
- Department of Chemistry
- University of Missouri
- Columbia
- USA
| | - Tim E. Phelps
- Department of Chemistry
- University of Missouri
- Columbia
- USA
| | | | - Fabio Gallazzi
- Structural Biology Core
- University of Missouri
- Columbia
- USA
| | - Gary Sieckman
- Research Division
- Harry S. Truman Memorial Veterans’ Hospital
- Columbia
- USA
| | | | | | - Alan R. Ketring
- University of Missouri Research Reactor Center (MURR)
- University of Missouri
- Columbia
- USA
| | - Heather M. Hennkens
- University of Missouri Research Reactor Center (MURR)
- University of Missouri
- Columbia
- USA
| | | |
Collapse
|
10
|
Gott MD, Hayes CR, Wycoff DE, Balkin ER, Smith BE, Pauzauskie PJ, Fassbender ME, Cutler CS, Ketring AR, Wilbur DS, Jurisson SS. Accelerator-based production of the 99mTc-186Re diagnostic-therapeutic pair using metal disulfide targets (MoS2, WS2, OsS2). Appl Radiat Isot 2016; 114:159-66. [PMID: 27236832 DOI: 10.1016/j.apradiso.2016.05.024] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2016] [Revised: 05/17/2016] [Accepted: 05/18/2016] [Indexed: 11/18/2022]
Affiliation(s)
- Matthew D Gott
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Connor R Hayes
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Donald E Wycoff
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States
| | - Ethan R Balkin
- Department of Radiation Oncology, University of Washington, Seattle, WA 98105, United States
| | - Bennett E Smith
- Department of Chemistry, University of Washington, Seattle, WA 98105, United States
| | - Peter J Pauzauskie
- Department of Materials Science and Engineering, University of Washington, Seattle, WA 98105, United States
| | - Michael E Fassbender
- Chemistry Division, Los Alamos National Laboratory, Los Alamos, NM 87545, United States
| | - Cathy S Cutler
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - Alan R Ketring
- University of Missouri Research Reactor Center, Columbia, MO 65211, United States
| | - D Scott Wilbur
- Department of Radiation Oncology, University of Washington, Seattle, WA 98105, United States
| | - Silvia S Jurisson
- Department of Chemistry, University of Missouri, Columbia, MO 65211, United States.
| |
Collapse
|
11
|
Fassbender ME, Ballard B, Birnbaum E, Engle J, John K, Maassen J, Nortier FM, Lenz J, Cutler CS, Ketring A, Jurisson SS, Wilbur D. Proton irradiation parameters and chemical separation procedure for the bulk production of high-specific-activity 186gRe using WO3 targets. RADIOCHIM ACTA 2013. [DOI: 10.1524/ract.2013.2031] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Abstract
Rhenium-186g (T
1/2= 89.2 h) is a β
− emitter suitable for therapeutic applications. Current production methods rely on reactor production via
185Re(n,γ) which results in low specific activities, thereby limiting its use. Production by p,d activation of enriched 186W results in a 186gRe product with a higher specific activity, allowing it to be used for targeted therapy with limited receptors. A test target consisting of pressed, sintered natWO3 was proton irradiated at Los Alamos (LANL-IPF) to evaluate product yield and impurities, irradiation parameters and wet chemical Re recovery for proof-of-concept for bulk production of 186gRe. We demonstrated isolation of 186gRe in 97% yield from irradiated natWO3 targets within 12 h of end of bombardment (EOB) via an alkaline dissolution followed by anion exchange. The recovery process has potential for automation, and WO3 can be easily recycled for recurrent irradiations. A 186gRe batch yield of 42.7 ± 2.2 μCi/μAh or 439 ± 23 MBq/C was obtained after 24 h in an 18.5 μA proton beam. The target entrance energy was determined to be 15.6 MeV. The specific activity of 186gRe at EOB was measured to be 1.9 kCi (70.3 TBq) mmol−1, which agrees well with the result of a previous 185,186mRe co-production EMPIRE and TALYS modeling study assuming similar conditions. Utilizing enriched 186WO3, we anticipate that a proton beam of 250 μA for 24 h will provide batch yields of 256 mCi (9.5 GBq) of 186gRe at EOB with specific activities even higher than 1.9 kCi (70.3 TBq) mmol−1, suitable for therapy applications.
Collapse
|
12
|
Cutler CS, Hennkens HM, Sisay N, Huclier-Markai S, Jurisson SS. Radiometals for Combined Imaging and Therapy. Chem Rev 2012. [DOI: 10.1021/cr3003104] [Citation(s) in RCA: 281] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Cathy S. Cutler
- University of Missouri Research Reactor Center, Columbia, Missouri 65211, United
States
| | - Heather M. Hennkens
- University of Missouri Research Reactor Center, Columbia, Missouri 65211, United
States
| | - Nebiat Sisay
- University of Missouri Research Reactor Center, Columbia, Missouri 65211, United
States
- Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United
States
| | - Sandrine Huclier-Markai
- Laboratoire Subatech,
UMR 6457, Ecole des Mines de Nantes/Université de Nantes/CNRS-IN2P3, 4 Rue A. Kastler, BP 20722, F-44307
Nantes Cedex 3, France
| | - Silvia S. Jurisson
- Department of Chemistry, University of Missouri, Columbia, Missouri 65211, United
States
| |
Collapse
|
13
|
Carroll V, Demoin DW, Hoffman TJ, Jurisson SS. Inorganic chemistry in nuclear imaging and radiotherapy: current and future directions. RADIOCHIM ACTA 2012; 100:653-667. [PMID: 25382874 PMCID: PMC4221859 DOI: 10.1524/ract.2012.1964] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Radiometals play an important role in diagnostic and therapeutic radiopharmaceuticals. This field of radiochemistry is multidisciplinary, involving radiometal production, separation of the radiometal from its target, chelate design for complexing the radiometal in a biologically stable environment, specific targeting of the radiometal to its in vivo site, and nuclear imaging and/or radiotherapy applications of the resultant radiopharmaceutical. The critical importance of inorganic chemistry in the design and application of radiometal-containing imaging and therapy agents is described from a historical perspective to future directions.
Collapse
Affiliation(s)
| | | | - Timothy J Hoffman
- Chemistry, University of Missouri, Columbia, MO 65211, USA
- Internal Medicine, University of Missouri, Columbia, MO 65211, USA
- Harry S Truman Memorial Veterans Hospital, Columbia, MO 65211, USA
| | | |
Collapse
|